

# Human papillomavirus (HPV) vaccines for Australians

This fact sheet provides information on HPV disease and the available vaccines to assist immunisation providers in the delivery of HPV vaccinations. It can be used in conjunction with the NCIRS resource: [HPV vaccines – frequently asked questions](#), which provides responses to common questions and concerns.

## Disease and epidemiology

- Human papillomavirus (HPV) is a common sexually transmitted infection in both males and females. Most people will acquire an HPV infection within a few years of becoming sexually active.
- A small proportion of HPV infections progress, usually over many years, to cancer. Cancers caused by HPV infection include cervical, vaginal, vulval, penile, anal, and some head and neck cancers.

## Who should be vaccinated

- HPV vaccine is recommended for adolescents aged 12–13 years and is included in the Australian National Immunisation Program (NIP). It is provided via school-based programs for this age group in a two-dose schedule. The second dose is given 6–12 months after the first dose.
- A three-dose schedule is recommended for individuals who commence vaccination at the age of 15 years or older, or for those with significant immunocompromising conditions, with doses given at an interval of 0, 2 and 6 months.
- Those who receive the vaccine before commencing sexual activity will benefit the most from HPV vaccination.
- HPV vaccination is not routinely recommended for adults, but is recommended for men who have sex with men and people with significant immunocompromising conditions, regardless of age.

## Vaccines

- The 9-valent HPV vaccine (9vHPV; Gardasil9), which protects against nine types of HPV, is the vaccine used in the NIP.
- The bivalent HPV vaccine (2vHPV; Cervarix) is available on the private market.
- HPV vaccines are safe and generally well tolerated. The most common side effect is a local reaction at the site of the injection.
- Vaccination does not prevent infection from all HPV types. Therefore, cervical screening remains an important preventive strategy against cervical cancer for women.

## The disease

Human papillomaviruses (HPVs) are small, non-enveloped DNA viruses. HPVs infect and replicate within cutaneous and mucosal epithelial tissues. There are 40 known HPV ‘types’ which infect the mucosal epithelium, classified according to sequence variation in the major genes.

Transmission of genital HPV occurs largely via sexual contact. There is a 50–80% chance of HPV transmission following unprotected sexual intercourse with a person with a current HPV infection.<sup>1-3</sup> The majority of genital HPV infections are subclinical and resolve spontaneously, clearing (i.e. no longer detectable) within 12–24 months of initial infection. Depending on the infecting HPV type, a small proportion of HPV infections can persist (estimated at 3–10%),<sup>4</sup> resulting in cellular abnormalities and, in a subset of cases, precancerous disease; a subset of these progress into cancer. The progression from mucosal HPV infection to cancer can take many years, and not all HPV infections progress to cancer.<sup>5-7</sup>

Of the mucosal HPV types, 13 are designated as ‘high-risk’ due to their causal association with the development of cervical cancer (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68).<sup>8</sup> These HPV types are also associated with the development of other cancers in females and males, including vaginal, anal and penile cancers, and head and neck cancers. HPV types 16 and 18 are the most common high-risk HPV types found in HPV-positive cervical cancers in Australia<sup>9</sup> and globally, and are the overwhelming cause of all HPV-related cancers.

Of the genital HPV types considered to be ‘low risk’, types 6 and 11 are major causes of genital warts (causing approximately 95% of genital warts) and recurrent respiratory papillomatosis.<sup>10</sup>

## Epidemiology of HPV infection and associated disease

HPV infection rates vary greatly between geographic regions and population groups. Around 90% of the general population will be infected with HPV at some point in their lives.<sup>11</sup> HPV infection rates among young women are highest soon after they become sexually active.<sup>12</sup> Aboriginal and Torres Strait Islander women have more than twice the risk of developing cervical cancer and a mortality rate four times that of non-Indigenous women.<sup>13,14</sup> However, in men, the risk of acquiring new HPV infection seems to remain stable over time.<sup>15</sup> A person’s lifetime number of sex partners is a significant predictor of HPV acquisition, although HPV is frequently acquired from a first and only sexual partner.<sup>16</sup>

The burden of HPV-associated cancers in males in Australia is less than that in women; however, the incidence of HPV-associated anal and tonsillar cancers has been increasing in males in recent decades while remaining relatively stable in females. Men who have sex with men are especially at high risk, with rates of vaccine-type HPV prevalence more than four times that in heterosexual men.<sup>17</sup> The estimated incidence of anal cancer among men who have sex with men in Australia is greater than that of cervical cancer in women prior to the introduction of cervical screening program.<sup>18</sup>

## Who should be vaccinated

### Routine vaccination under the National Immunisation Program

HPV vaccination is recommended for adolescents aged 12–13 years in a two-dose schedule (0, 6–12 months) using the 9vHPV vaccine. Vaccination is mainly delivered through school-based programs, but is available to people aged <20 years who need to catch up on vaccination.

## Other recommendations for vaccination

### People who are immunocompromised

People who are immunocompromised have a higher risk of persistent HPV infection and related disease. The conditions where the three-dose schedule is required include primary or secondary immunodeficiencies (B lymphocyte antibody and T lymphocyte complete or partial deficiencies), HIV infection, malignancy, organ transplantation or significant immunosuppressive therapy.

### Men who have sex with men

Men who have sex with men are recommended to receive HPV vaccination because of their increased risk of HPV infection and associated disease, notably genital warts and anal cancer.<sup>18</sup> They are also less likely to benefit from herd protection attained from HPV vaccination of females.

### Women treated for high-grade cervical disease

HPV vaccination should be considered for women who have received treatment for cervical intraepithelial neoplasia (CIN) 2+ (i.e. high-grade cervical disease) to reduce future susceptibility to HPV-related disease. The vaccine will have no impact on current infection or disease but can prevent reinfection (e.g. from a partner), spread of infection through the genital tract and new infection with other HPV types covered by the vaccine.<sup>19</sup>

### Adults aged ≥19 years

Vaccination of all adults aged 19 years and older is not routinely recommended, as the benefits of vaccination are lower in those already exposed to vaccine HPV types through sexual activity.

A recent study estimated that of all the HPV infections that cause cervical cancer, 50% have been acquired by age 20 and 75% by the age of 30.<sup>20</sup> Thus the capacity to benefit from HPV immunisation decreases with increasing age. Cervical cancer prevention in sexually active women (whether vaccinated or not) is best achieved through cervical screening.<sup>9</sup>

## Vaccines

All HPV vaccines contain virus-like particles (VLPs) which are made using recombinant vaccine technology. They are not live vaccines. HPV vaccines are not therapeutic vaccines and will not clear an existing HPV infection. HPV vaccines elicit antibody titres many times higher than those observed in natural infection.<sup>21-25</sup>

### 9-valent HPV vaccine

Gardasil9 (Seqirus/Merck & Co Inc) is a 9-valent HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58) registered in Australia for use in females aged 9–45 years and males aged 9–26 years. Gardasil9 is the HPV vaccine used in Australia's National HPV Vaccination Program.

### Quadrivalent HPV vaccine

Gardasil (Seqirus/Merck & Co Inc) is a quadrivalent VLP HPV vaccine (4vHPV; types 16, 18, 6 and 11) registered in Australia for use in females aged 9–45 years and in males aged 9–26 years. Gardasil was used in the National HPV Vaccination Program from 2007 to 2017, but has been replaced by Gardasil9 since 2018.

### Bivalent HPV vaccine

Cervarix (GlaxoSmithKline) is a bivalent VLP HPV vaccine (2vHPV; types 16 and 18) registered in Australia for use in females aged 10–45 years. Cervarix is not registered for use in males of any age. It is supplied in Australia only on the private market.

## Dose and route

The dose of 9vHPV, 4vHPV and 2vHPV vaccine is 0.5 mL administered intramuscularly.

A two-dose schedule is recommended for those who receive their first HPV vaccine dose before their 15th birthday, administered at 0 (the day the first dose is given) and 6–12 months. If an individual has received two doses of HPV vaccine with an interval of <5 months between dose 1 and dose 2, then a third dose is needed at least 12 weeks after the second dose.

A three-dose schedule is recommended for anyone who is immunocompromised (any age) and those who receive their first HPV vaccine dose on or after their 15th birthday, administered at 0, 1 and 6 months for 2vHPV vaccine, and at 0, 2 and 6 months for 9vHPV and 4vHPV vaccines. Older adolescents (who are not immunocompromised) who commence vaccination after turning 15 years may need to pay to complete the schedule, as only two doses are funded.

The minimum acceptable interval for HPV vaccines in a three-dose schedule is 4 weeks between doses 1 and 2, and 12 weeks between doses 2 and 3. A minimum interval of 5 months is required between dose 1 and dose 3.

If scheduled doses have been missed, earlier doses should not be repeated. The missed dose(s) should be given as soon as practicable.

Re-vaccination with the 9vHPV vaccine is not routinely recommended for those who have previously completed an HPV vaccination schedule with either 4vHPV or 2vHPV vaccine.

The World Health Organization recently recommended that HPV vaccine can be used in a one-dose schedule for people aged 9 to <20 years and in a two-dose schedule for people aged ≥21 years.<sup>26</sup> However, the vaccination schedule remains unchanged in Australia.

Pre-immunisation screening with HPV tests or by serological testing is not warranted.

## Vaccine efficacy/effectiveness

The efficacy of HPV vaccines has been extensively assessed in clinical trials enrolling females. In women who are naïve to (i.e. have never been infected with) the vaccine HPV types, 9vHPV vaccine is highly effective (>96%) in preventing persistent-type specific infection and high-grade cervical, vulvar and vaginal disease associated with these HPV types.<sup>27</sup> Younger adolescents, both female and male, aged 9–14 years develop higher levels of HPV antibodies than older adolescents and young women in whom clinical efficacy has been demonstrated.<sup>24,25,28</sup> Similarly, 4vHPV and 2vHPV vaccines are highly efficacious and immunogenic against their respective HPV types.<sup>21,23-25,29-34</sup>

HPV vaccination has been hugely successful in reducing rates of HPV-associated disease in Australia.<sup>35</sup> Since the HPV vaccination program began in 2007, rates of genital warts have declined by more than 90% in younger vaccinated populations.<sup>36</sup> The incidence of high-grade cervical abnormalities has decreased in women up to 30 years of age.<sup>13,37,38</sup> High rates of HPV vaccination have resulted in declines in the prevalence of 4vHPV types among Aboriginal and Torres Strait Islander women by up to 94%.<sup>39</sup> These declines are expected to translate into declines in cervical cancer in the coming years and can reduce disparities in cervical cancer incidence among Aboriginal and Torres Strait Islander and non-Indigenous women. Australia is currently working towards achieving the elimination of cervical cancer by 2035; however, with continued high rates of vaccination and cervical screening, this could happen by 2028.<sup>40,41</sup>

Among men, HPV vaccination prevented more than 85% of persistent anogenital infections and external genital lesions due to 4vHPV types among HPV-naïve participants. Among participants who were men who have sex with men, vaccine efficacy was 95% against intra-anal HPV

infection and 75% against high grade anal intraepithelial neoplasia from vaccine HPV types. A recent study of men who have sex with men in Victoria found that up to 29% of new HPV infections could have been prevented through vaccination with 9vHPV vaccine.<sup>42</sup>

Duration of immunity through vaccination is likely to be long-term, with stable antibody titres demonstrated for over 10 years after immunisation with 2vHPV and 4vHPV vaccines and up to 8 years with 9vHPV vaccine.<sup>27,43-45 46</sup> Pre-adolescent males and females have a good immune response to vaccination, producing higher antibody levels than young women.<sup>24,47,48</sup>

## Vaccine safety

HPV vaccines are included in national immunisation schedules in 107 countries,<sup>49,50</sup> with more than 270 million doses distributed worldwide.<sup>51</sup> Extensive data from clinical trial and post-marketing safety surveillance indicate that the 9vHPV, 4vHPV and 2vHPV vaccines are well tolerated and safe.<sup>52-54</sup>

The main side effects of the vaccines are local reactions at the injection site (pain, redness and swelling). These reactions occur in about 80–90% of vaccine recipients but are less frequent in younger girls and in boys than in adult women.<sup>47,55,56</sup> Syncope (fainting) is one of the more commonly reported adverse events that was reported when HPV vaccine was first introduced (reported at a rate of 29.6 per 100,000), but is now very rarely reported (7.1 per 100,000 doses<sup>57</sup>). The 9vHPV vaccine has demonstrated a similar safety profile to that of the 4vHPV vaccine, but with a slightly increased frequency in injection site reactions, likely due to the increased concentration of adjuvant.<sup>52,58</sup> Data from multiple clinical trials and post-marketing use show that the 9vHPV, 4vHPV and 2vHPV vaccines do not increase the risk of serious adverse events (SAEs) among vaccine recipients compared with control/placebo recipients.<sup>56,58-61</sup>

There is no strong scientific or epidemiological evidence to suggest that HPV vaccines can induce syndromes such as premature ovarian failure (POF), postural tachycardia syndrome (POTS) or complex regional pain syndrome (CRPS).<sup>62</sup> These diseases of unclear aetiology unfortunately occur in adolescents and young people, whether they are vaccinated or unvaccinated, and there is no evidence that these conditions occur more frequently in HPV-vaccinated populations. There is also no evidence that HPV vaccination is linked to infertility.<sup>63,64</sup> The Global Advisory Committee on Vaccine Safety of the World Health Organization has reviewed HPV vaccines nine times – most recently in 2019 – and continues to endorse their safety and use in young adolescents.<sup>64</sup>

## Concomitant administration with other vaccines

9vHPV vaccine has been assessed in clinical trials when delivered concomitantly (at the same visit but at a separate injection site with a separate syringe) with reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) and quadrivalent meningococcal (A, C, W<sub>135</sub>, Y) conjugate vaccine (4vMenCV).<sup>65,66</sup> Co-administration was well tolerated and induced a robust immune response to all vaccines. HPV vaccine can be co-administered with COVID-19 vaccines.<sup>67</sup>

## Interchangeability

9vHPV vaccine can be used to complete an HPV vaccination schedule commenced with either 4vHPV vaccine or 2vHPV vaccine. Previously administered doses do not need to be repeated (if given at the appropriate interval), regardless of the time since those doses were administered.

## Contraindications/precautions

HPV vaccine should not be given to anyone who has experienced an anaphylactic reaction after a previous dose of the vaccine or to any component of the respective vaccine (including yeast for 9vHPV and 4vHPV vaccines).

HPV vaccine should not be administered during pregnancy. If an HPV vaccine is inadvertently administered during pregnancy, the rest of the vaccination schedule should be deferred until after pregnancy. Females who inadvertently receive a dose of HPV vaccine around the time of conception or during pregnancy should be informed that the scientific evidence suggests there is no harm to the pregnant woman or her foetus. For more information on vaccine safety during pregnancy, refer to the [Australian Immunisation Handbook](#).

## Other considerations

### Cervical screening in women who have been vaccinated

Regular cervical screening tests are still recommended, as per national guidelines under the renewed National Cervical Screening Program, for women who have received HPV vaccine. Screening for women aged 25–74 years is recommended every 5 years (or 2 years after the last Pap test). In sexually active women, the most important preventive intervention against cervical disease remains regular cervical screening. Vaccination is *not* an 'alternative' to cervical screening; together these two approaches provide optimal protection against disease.

More information about the National Cervical Screening Program can be found at: <http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-screening-1>.

### Responding to questions about HPV vaccine

Please see the NCIRS fact sheet [HPV vaccines – frequently asked questions](#) for information to assist providers in answering patient concerns about the vaccine.

## Additional resources for primary medical care/vaccination providers

- [The Australian Immunisation Handbook](#)
- [Immunisation Australia website](#)

## References

1. National Health and Medical Research Council (NHMRC). Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra: NHMRC; 2005.  
[http://www.nhmrc.gov.au/\\_files\\_nhmrc/file/publications/synopses/wh39.pdf](http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/wh39.pdf)
2. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. *PLoS Medicine* 2006;3:e138.
3. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. *Epidemiology* 2002;13:631-9.

4. Monson J, Bosch FX, Coursaget P, et al. Cervical cancer control, priorities and new directions. *International Journal of Cancer* 2004;108:329-33.
5. World Health Organization, International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans. Volume 90. Human papillomaviruses. Lyon, France: IARC; 2007.  
<http://monographs.iarc.fr/ENG/Monographs/vol90/mono90.pdf>
6. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. *Journal of Adolescent Health* 2010;46(4 Suppl):S20-6.
7. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *The Lancet Oncology* 2012;13:607-15.
8. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents. *The Lancet Oncology* 2009;10:321-2.
9. Brotherton JML, Tabrizi SN, Phillips S, et al. Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. *International Journal of Cancer* 2017;141:1576-84.
10. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. *Journal of Infectious Diseases* 2009;199:805-14.
11. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. *Sexually Transmitted Diseases* 2014;41:660-4.
12. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. *Journal of Adolescent Health* 2008;43:S5-25.
13. Australian Institute of Health and Welfare. National Cervical Screening Program monitoring report 2021. Canberra: AIHW; 2021. <https://www.aihw.gov.au/getmedia/2a26ae22-2f84-4d75-a656-23c329e476bb/aihw-can-141.pdf.aspx?inline=true>
14. Whop LJ, Garvey G, Baade P, et al. The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011). *Cancer* 2016;122:1560-9.
15. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of human papillomavirus infection in males: a global review. *Journal of Adolescent Health* 2011;48:540-52.
16. Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. *Journal of Infectious Diseases* 2008;197:279-82.
17. Wei F, Gaisa MM, D'Souza G, et al. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. *Lancet HIV* 2021;8:e531-e43.
18. Georgousakis M, Jayasinghe S, Brotherton J, et al. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. *The Lancet Infectious Diseases* 2012;12:627-34.
19. Brotherton JM, Wrede CD. Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: what do you need to know? *Australian and New Zealand Journal of Obstetrics and Gynaecology* 2014;54:393-4.

20. Burger EA, Kim JJ, Sy S, Castle PE. Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer. *Clinical Infectious Diseases* 2017;65:893-9.
21. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. *The Lancet Oncology* 2005;6:271-8.
22. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *The Lancet* 2006;367:1247-55.
23. US Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee meeting, May 18, 2006. Briefing information. 2006. (Accessed 7 March 2018). <http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222b-index.htm>
24. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. *JAMA* 2016;316:2411-21.
25. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *New England Journal of Medicine* 2015;372:711-23.
26. World Health Organization. Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 4-7 April 2022. 2022. (Accessed 3 June 2022). [https://cdn.who.int/media/docs/default-source/reproductive-health/sage\\_april2022meetinghighlights\\_11apr2022\\_final.pdf?sfvrsn=21bcfb4f\\_3](https://cdn.who.int/media/docs/default-source/reproductive-health/sage_april2022meetinghighlights_11apr2022_final.pdf?sfvrsn=21bcfb4f_3)
27. Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. *The Lancet* 2017;390:2143-59.
28. Petersen LK, Restrepo J, Moreira ED, Jr., et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. *Papillomavirus Res* 2017;3:105-15.
29. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. *JAMA* 2013;309:1793-802.
30. Romanowski B, de Borja PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. *The Lancet* 2009;374:1975-85.
31. Puthanakit T, Huang LM, Chiu CH, et al. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. *Journal of Infectious Diseases* 2016;214:525-36.
32. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *New England Journal of Medicine* 2007;356:1928-43.
33. FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. *The Lancet* 2007;369:1861-8.



34. Castellsague X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. *Vaccine* 2015;33:6892-901.
35. Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? *Euro Surveill* 2018;23.
36. Khawar L, McManus H, Vickers T, et al. Genital warts trends in Australian and overseas-born people in Australia: A cross-sectional trend analysis to measure progress towards control and elimination. *The Lancet Regional Health - Western Pacific* 2021;16:100251.
37. Brotherton JM, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. *Medical Journal of Australia* 2016;204:184-e1.
38. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. *The Lancet* 2011;377:2085-92.
39. McGregor S, Saulo D, Brotherton JML, et al. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study. *Vaccine* 2018;36:4311-6.
40. NHMRC Centre of Research Excellence in Cervical Cancer Control. 2021 cervical cancer elimination progress report: Australia's progress towards the elimination of cervical cancer as a public health problem. 2021. (Accessed 3 June 2022). <https://kirby.unsw.edu.au/sites/default/files/kirby/report/Cervical-Cancer-Elimination-Progress-Report-2021.pdf>
41. Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. *Lancet Public Health* 2019;4:e19-e27.
42. Ong JJ, Walker S, Grulich A, et al. Incidence, clearance, and persistence of anal human papillomavirus in men who have sex with men living with human immunodeficiency virus: Implications for human papillomavirus vaccination. *Sexually Transmitted Diseases* 2019;46:229-33.
43. Das R, Saah A, Iversen OE. Effectiveness, immunogenicity, and safety of Gardasil™ in pre-adolescents and adolescents – 10 years of follow-up [abstract 13-03]. Presented at: Eurogin 2016; June 2016; Salzburg, Austria. (Accessed Aug 2017). <http://eurogin.com/2016/>
44. Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials. *BMJ Open* 2017;7:e015867.
45. Olsson SE, Restrepo JA, Reina JC, et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. *Papillomavirus Research* 2020;10:100203.
46. Guevara A, Cabello R, Woelber L, et al. Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine. *Vaccine* 2017;35:5050-7.
47. Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine. *Pediatrics* 2015;136:e28-39.

48. Bornstein J, Roux S, Kjeld Petersen L, et al. Three-year follow-up of 2-dose versus 3-dose HPV vaccine. *Pediatrics* 2021;147.
49. Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. *Best Pract Res Clin Obstet Gynaecol* 2018;47:42-58.
50. Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. *Preventive Medicine* 2021;144:106399.
51. World Health Organization (WHO). Meeting of the Global Advisory Committee on Vaccine Safety, 7–8 June 2017. *Weekly Epidemiological Record* 2017;92:393-402.
52. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. *Drug Saf* 2017.
53. Shimabukuro TT, Su JR, Marquez PL, et al. Safety of the 9-valent human papillomavirus vaccine. *Pediatrics* 2019;144.
54. Donahue JG, Kieke BA, Lewis EM, et al. Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine. *Pediatrics* 2019;144.
55. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. *Drug Safety* 2013;36:393-412.
56. Moreira ED, Jr., Block SL, Ferris D, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. *Pediatrics* 2016;138.
57. Phillips A, Hickie M, Totterdell J, et al. Adverse events following HPV vaccination: 11 years of surveillance in Australia. *Vaccine* 2020;38:6038-46.
58. Costa APF, Cobucci RNO, da Silva JM, et al. Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials. *J Immunol Res* 2017;2017:3736201.
59. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. *BMC Infectious Diseases* 2011;11:13.
60. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. *CMAJ Canadian Medical Association Journal* 2007;177:469-79.
61. Yih WK, Kulldorff M, Dashevsky I, Maro JC. A broad safety assessment of the 9-valent human papillomavirus vaccine. *American Journal of Epidemiology* 2021;190:1253-9.
62. World Health Organization (WHO). Global Advisory Committee on Vaccine Safety, 2–3 December 2015. *Weekly Epidemiological Record* 2016;91:21-31.
63. Schmuhl NB, Mooney KE, Zhang X, et al. No association between HPV vaccination and infertility in U.S. females 18-33 years old. *Vaccine* 2020;38:4038-43.
64. World health Organization. WHO GACVS report December 2019. 2019. (Accessed 3 June 2022). <https://www.who.int/publications/m/item/WER-202095-4>
65. Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and

poliomyelitis vaccines to healthy adolescents 11-15 years of age. *Pediatric Infectious Disease Journal* 2015;34:627-34.

66. Schilling A, Parra MM, Gutierrez M, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. *Pediatrics* 2015;136:e563-72.
67. Australian Technical Advisory Group on Immunisation (ATAGI). Clinical recommendations for COVID-19 vaccines. Canberra, Australia: Australian Government Department of Health; 2022. (Accessed 14 June 2022). <https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations>